118 research outputs found
Treatment of psychoses in patients with epilepsy: an update.
Psychotic disorders represent a relatively rare but serious comorbidity in epilepsy. Current epidemiological studies are showing a point prevalence of 5.6% in unselected samples of people with epilepsy going up to 7% in patients with temporal lobe epilepsy, with a pooled odds ratio of 7.8 as compared with the general population. This is a narrative review of the most recent updates in the management of psychotic disorders in epilepsy, taking into account the clinical scenarios where psychotic symptoms occur in epilepsy, interactions with antiepileptic drugs (AEDs) and the risk of seizures with antipsychotics. Psychotic symptoms in epilepsy can arise in a number of different clinical scenarios from peri-ictal symptoms, to chronic interictal psychoses, comorbid schizophrenia and related disorders to the so-called forced normalization phenomenon. Data on the treatment of psychotic disorders in epilepsy are still limited and the management of these problems is still based on individual clinical experience. For this reason, guidelines of treatment outside epilepsy should be adopted taking into account epilepsy-related issues including interactions with AEDs and seizure risk. Second-generation antipsychotics, especially risperidone, can represent a reasonable first-line option because of the low propensity for drug-drug interactions and the low risk of seizures. Quetiapine is burdened by a clinically significant pharmacokinetic interaction with enzyme-inducing drugs leading to undetectable levels of the antipsychotic, even for dosages up to 700 mg per day
Neurostimulatory and ablative treatment options in major depressive disorder: a systematic review
Introduction Major depressive disorder is one of the most disabling and common diagnoses amongst psychiatric disorders, with a current worldwide prevalence of 5-10% of the general population and up to 20-25% for the lifetime period. Historical perspective Nowadays, conventional treatment includes psychotherapy and pharmacotherapy; however, more than 60% of the treated patients respond unsatisfactorily, and almost one fifth becomes refractory to these therapies at long-term follow-up. Nonpharmacological techniques Growing social incapacity and economic burdens make the medical community strive for better therapies, with fewer complications. Various nonpharmacological techniques like electroconvulsive therapy, vagus nerve stimulation, transcranial magnetic stimulation, lesion surgery, and deep brain stimulation have been developed for this purpose. Discussion We reviewed the literature from the beginning of the twentieth century until July 2009 and described the early clinical effects and main reported complications of these methods. © The Author(s) 2010.Link_to_subscribed_fulltex
Semiconductor Spintronics
Spintronics refers commonly to phenomena in which the spin of electrons in a
solid state environment plays the determining role. In a more narrow sense
spintronics is an emerging research field of electronics: spintronics devices
are based on a spin control of electronics, or on an electrical and optical
control of spin or magnetism. This review presents selected themes of
semiconductor spintronics, introducing important concepts in spin transport,
spin injection, Silsbee-Johnson spin-charge coupling, and spindependent
tunneling, as well as spin relaxation and spin dynamics. The most fundamental
spin-dependent nteraction in nonmagnetic semiconductors is spin-orbit coupling.
Depending on the crystal symmetries of the material, as well as on the
structural properties of semiconductor based heterostructures, the spin-orbit
coupling takes on different functional forms, giving a nice playground of
effective spin-orbit Hamiltonians. The effective Hamiltonians for the most
relevant classes of materials and heterostructures are derived here from
realistic electronic band structure descriptions. Most semiconductor device
systems are still theoretical concepts, waiting for experimental
demonstrations. A review of selected proposed, and a few demonstrated devices
is presented, with detailed description of two important classes: magnetic
resonant tunnel structures and bipolar magnetic diodes and transistors. In most
cases the presentation is of tutorial style, introducing the essential
theoretical formalism at an accessible level, with case-study-like
illustrations of actual experimental results, as well as with brief reviews of
relevant recent achievements in the field.Comment: tutorial review; 342 pages, 132 figure
Treatment of psychoses in patients with epilepsy: an update.
Psychotic disorders represent a relatively rare but serious comorbidity in epilepsy. Current epidemiological studies are showing a point prevalence of 5.6% in unselected samples of people with epilepsy going up to 7% in patients with temporal lobe epilepsy, with a pooled odds ratio of 7.8 as compared with the general population. This is a narrative review of the most recent updates in the management of psychotic disorders in epilepsy, taking into account the clinical scenarios where psychotic symptoms occur in epilepsy, interactions with antiepileptic drugs (AEDs) and the risk of seizures with antipsychotics. Psychotic symptoms in epilepsy can arise in a number of different clinical scenarios from peri-ictal symptoms, to chronic interictal psychoses, comorbid schizophrenia and related disorders to the so-called forced normalization phenomenon. Data on the treatment of psychotic disorders in epilepsy are still limited and the management of these problems is still based on individual clinical experience. For this reason, guidelines of treatment outside epilepsy should be adopted taking into account epilepsy-related issues including interactions with AEDs and seizure risk. Second-generation antipsychotics, especially risperidone, can represent a reasonable first-line option because of the low propensity for drug-drug interactions and the low risk of seizures. Quetiapine is burdened by a clinically significant pharmacokinetic interaction with enzyme-inducing drugs leading to undetectable levels of the antipsychotic, even for dosages up to 700 mg per day
- …